Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.09 USD
Change Today -0.04 / -3.54%
Volume 172.2K
ATHX On Other Exchanges
As of 12:45 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3201 Carnegie Avenue

Cleveland, OH 44115

United States

Phone: 216-431-9900

Fax: 216-361-9495

Athersys, Inc., an international biotechnology company, focuses primarily in the field of regenerative medicine. The company engages in the discovery and development of therapies designed to extend and improve the quality of human life. The company has established a portfolio of therapeutic product development programs to address significant unmet medical needs in multiple disease areas. The company’s MultiStem cell therapy, a patented and proprietary allogeneic stem cell product, is the company’s major platform product and has been evaluated in two completed Phase 1 clinical trials and is being evaluated in Phase 2 clinical trials, as well as an investigator-led Phase 1 trial, and plans are underway for a Phase 2/3 registration clinical trial. The company’s clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company is also applying its pharmaceutical discovery capabilities to identify and develop small molecule compounds with potential applications in indications, such as obesity, related metabolic conditions and certain neurological conditions. These represent major areas of clinical need, as well as substantial commercial opportunities. In February 2015, the company established a collaboration with Chugai Pharmaceutical Co., Ltd. (Chugai) to develop and commercialize MultiStem for the treatment of ischemic stroke in Japan. Chugai would be responsible for the development and commercialization of MultiStem for ischemic stroke in Japan on an exclusive basis, and the company would have the primary responsibility for the manufacture of product for both clinical and commercial purposes. The company is also in the process of initiating a Phase 2 clinical study for the administration of MultiStem cell therapy to patients that have suffered an acute myocardial infarction (AMI). Additionally, the company evaluated in a completed Phase 1 clinical study the potential for MultiStem cell therapy to prevent or reduce graft-versus-host disease (GvHD) and other complications, and to provide supportive care to patients undergoing a hematopoietic stem cell transplant to treat leukemia or related conditions. The company is preparing to advance its GvHD program into the next phase of clinical development and has had various interactions with the United States Food and Drug Administration (FDA) and similar international agencies regarding study design and the potential to accelerate the path to product approval. The company also engages in the preparation stages for clinical studies in other targeted areas, including the treatment of acute respiratory distress syndrome (ARDS). ARDS is a serious immunological and inflammatory condition characterized by widespread inflammation in the lungs. The company’s collaborative partner, Pfizer Inc. (Pfizer), is completing a Phase 2 clinical study exploring administration of MultiStem to patients with ulcerative colitis (UC), a common form of inflammatory bowel disease (IBD). Programs The company’s programs in the clinical development stage include the following: Ischemic Stroke: In the company’s ongoing Phase 2 clinical study, it is evaluating the administration of MultiStem cell therapy to patients that have suffered an ischemic stroke. In contrast to treatment with the thrombolytic tPA, which must be administered within three to four hours after a stroke, the company is treating patients one to two days after the stroke has occurred. This double blind, placebo-controlled trial is being conducted at major stroke centers across the United States and Europe. Enrollment was completed in 2014. AMI: The company evaluated the administration of MultiStem to patients that suffered an AMI in a Phase 1 clinical study. The company is completing preparations for the launch of this Phase 2 clinical study, which it anticipates would commence in the second quarter of 2015. ARDS: The company is awarded a grant to support an initial trial to treat patients suffering from ARDS. The grant supporting this Phase 2a clinical trial is awarded by Innovate UK to the company’s sub


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATHX:US $1.09 USD -0.04

ATHX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $5.50 USD -0.20
Cytori Therapeutics Inc $0.36 USD -0.013
IntelliCell BioSciences Inc $0.0002 USD 0.00
Pluristem Therapeutics Inc $1.75 USD -0.0235
StemCells Inc $0.42 USD -0.0299
View Industry Companies

Industry Analysis


Industry Average

Valuation ATHX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 60.7x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 38.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATHERSYS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at